Our trustees include parents of children who had leukaemia, or experts in very high risk leukaemia working in leading positions across industry
They each bring a unique perspective to this urgent issue, but share their ambition and passion for change
The Scientific Advisory Board (SAB) of the Kaiya Foundation consist of the world leading scientific and clinical experts in VHR leukemia. Beyond their unrivaled track record in VHR leukaemia, the foundation considered their scientific focus, geographical location, and involvement in relevant clinical consortia. Furthermore, their ambition in driving relevant change and cutting-edge innovation in the field that aligns with the Foundation’s vision was assessed.
The five appointed SAB members, all active physician-scientists from renown institutions, represent the arguably strongest and most focused expert panel for VHR leukaemia. Together, they cover all significant ongoing pre-clinical and clinical VHR leukemia efforts, and are involved in all relevant discussions and new projects across the US and Europe.
Adam Craig, MD, PhD, MBA, has more than 25 years of drug development, regulatory and commercialization experience in the biopharmaceutical industry. Most recently, Dr Craig was President, CEO and Interim Chief Medical Officer at CTI BioPharma Corp. (NASDAQ: CTIC) where he successfully led the FDA approval and commercialization of the novel myelofibrosis therapy VONJO (pacritinib), resulting in the successful acquisition of CTI by Swedish Orphan Biovitrum AB for $1.7BN.
Prior to CTI, Dr. Craig was Chief Medical Officer and Executive Vice President of Development at Sunesis Pharmaceuticals, Interim Chief Medical Officer at Immune Design, and Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd (acquired by Cephalon/Teva Pharmaceuticals). He has served as a Product Development Reviewer for the $3BN Cancer Prevention Research Institute of Texas. Dr Craig is an author of numerous publications and abstracts in the field of hematology, oncology and drug development. He is currently a strategic advisor to public and private company boards, venture capital, hedge and private equity funds, and has recently established a mentoring program for mid-level executives in the pharmaceutical industry.
